The effects of parathyroid hormone, alendronate, or both in men with osteoporosis

New England Journal of Medicine

Volumn 349, Issue 13, 2003, Pages 1216-1226

  Finkelstein, Joel S ^a   Hayes, Annmarie ^a   Hunzelman, Joy L ^a   Wyland, Jason J ^a   Lee, Hang ^a   Neer, Robert M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALKALINE PHOSPHATASE; PARATHYROID HORMONE; CALCIUM; PARATHYROID HORMONE[1-34]; VITAMIN D;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; CALCIUM INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HIP; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; LUMBAR SPINE; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; BLOOD; BONE REMODELING; DRUG COMBINATION; DRUG EFFECT; LUMBAR VERTEBRA; MIDDLE AGED; PATHOLOGY; PATIENT COMPLIANCE; RADIODENSITOMETRY; RADIOGRAPHY; RADIUS; SUBCUTANEOUS DRUG ADMINISTRATION; URINE;

AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; BONE DENSITY; BONE REMODELING; CALCIUM; DENSITOMETRY, X-RAY; DRUG THERAPY, COMBINATION; FEMUR NECK; HUMANS; INJECTIONS, SUBCUTANEOUS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; RADIUS; TERIPARATIDE; VITAMIN D;

EID: 0141796739     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa035725     Document Type: Article

References (37)

1. Finkelstein JS. Osteoporosis. In: Goldman L, Bennett JC, eds. Cecil textbook of medicine. 21st ed. Philadelphia: W.B. Saunders, 2000:1366-73.
2. Melton LJ. Epidemiology of fractures. In: Orwoll ES, ed. Osteoporosis in men: the effects of gender on skeletal health. San Diego, Calif.: Academic Press, 1999:1-13.
3. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999;96:133-8.
4. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
5. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
6. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280: 2077-82.
7. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001;86: 5252-5.
8. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
9. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay K, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-76.
10. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.
11. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994;331:1618-23.
12. Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized, controlled trial. JAMA 1998; 280:1067-73.
13. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
14. Taylor A, Konrad PT, Norman ME, Harcke HT. Total body bone mineral density in young children: influence of head bone mineral density. J Bone Miner Res 1997;12: 652-5.
15. Rosenthal DI, Ganott MA, Wyshak G, Slovik DM, Doppelt SH, Neer RM. Quantitative computed tomography for spinal density measurement: factors affecting precision. Invest Radiol 1985;20:306-10.
16. Bikle D. Biochemical markers in the assessment of bone disease. Am J Med 1997; 103:427-36.
17. Neer R, Hayes A, Rao A, Finkelstein J. Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women. J Bone Miner Res 2002; 17:Suppl 1:S135. abstract.
18. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15.
19. Hock JM, Hummert JR, Boyce R, Fonseca J, Raisz LG. Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo. J Bone Miner Res 1989; 4:449-58.
20. Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 1992;7:65-72.
21. Baumann BD, Wronski TJ. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 1995;16:247-53.
22. Wronski TJ, Yen C-F, Qi H, Dann LM. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 1993;132:823-31.
23. Ma YL, Bryant HU, Zeng Q, et al. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 2003;144:2008-15.
24. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate - is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 1995;16:603-10.
25. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5.
26. Roe EB, Sanchez SD, del Puerto GA, et al. Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis - results from a placebo-controlled randomized trial. J Bone Miner Res 1999;14: Suppl 1:S137. abstract.
27. Hodsman AB, Steer BM, Fraher LJ, Drost DJ. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner 1991;14:67-83.
28. Hodsman AB, Fraher J, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997;82:620-8.
29. Ellinger B, San Martin JA, Crans G, Pavo I. Early response of bone turnover markers and bone mineral density to teriparatide [recombinant human parathyroid hormone (1-34)] in postmenopausal women previously treated with an antiresorptive drug. J Bone Miner Res 2002;17:Suppl 1:S157. abstract.
30. Finkelstein JS. Pharmacological mechanisms of therapeutics: parathyroid hormone. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. 2nd ed. Vol. 2. San Diego, Calif.: Academic Press, 1996: 993-1005.
31. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:4528-35.
32. Neer R, Slovik D, Daly M, Lo C, Potts J, Nussbaum S. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990: proceedings of the Third International Symposium on Osteoporosis. Vol. 3. Copenhagen, Denmark: Osteopress ApS, 1990:1314-7.
33. Canalis E, Centrella M, Burch W, McCarthy TL. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 1989; 83:60-5.
34. McCarthy TL, Centrella M, Canalis E. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology 1989;124:1247-53.
35. Oreffo ROC, Mundy GR, Seyedin SM, Bonewald LF. Activation of the bone derived latent TGF-β complex by isolated osteoclasts. Biochem Biophys Res Commun 1989; 158:817-23.
36. Slovik DM, Rosenthal DI, Doppelt SH, et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1986;1: 377-81.
37. Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998; 13:1051-5.